Latest news with #healthindustry
Yahoo
6 days ago
- Business
- Yahoo
Scale Hits New High: HNC 2025 Concludes with Resounding Success, Driving a New Wave of Health Industry Upgrades
SHANGHAI, July 18, 2025 /PRNewswire/ -- Jointly organized by the China Chamber of Commerce for Import & Export of Medicines & Health Products and Sinoexpo Informa Markets, the "Healthplex Expo 2025, Natural & Nutraceutical Products China 2025" (HNC 2025) was successfully held from June 24 to 26 at the National Exhibition and Convention Center (Shanghai). The HNC 2025 once again achieved a historic breakthrough in scale, winning high praise from all participants. Held concurrently with Hi & Fi Asia-China, ProPak China & FoodPack China, and Starch Expo, the HNC built a business platform integrating the entire industry chain from upstream ingredient supply to end-product distribution. The total exhibition area exceeded 200,000 sqm, bringing together more than 2,500 exhibitors from around the world. Meanwhile, 93,080 professional buyers from 137 countries and regions attended the shows for business exchange and negotiation — a year-on-year increase of 21.2% — fully showcasing the latest achievements and future directions of the health industry, and highlighting its tremendous vitality and boundless potential. The HNC deeply aggregates global resources and builds an industry ecosystem for collaborative development. This year's HNC not only gathered leading enterprises from across China but also attracted industry leaders from more than 30 countries and regions, including Australia, New Zealand, Italy, South Korea, Japan, Malaysia, the United States, Canada, Singapore, Spain, Norway, etc. National pavilions and exhibitors from Italy, Spain, Slovenia, the United States, and Japan made their debuts in China at the exhibition. Local delegations from across China also demonstrated their regional strengths — for example, Jilin pavilion featured its renowned ginseng and antler products, while Xizang pavilion presented its unique highland resources and premium wellness treasures. Both domestic and international exhibitors displayed a diverse range of products and solutions spanning nutritional and health supplements, imported dietary supplements, traditional tonic foods, health foods and beverages, anti-aging beauty products, emotional healing solutions, weight management products, healthcare devices and equipment, as well as third-party professional services. As a vital platform for information exchange, product launches, technology discussions, and market expansion in the health industry, HNC continues to attract a growing number of domestic and international companies, driving deeper collaboration and development across the global health and nutrition sector. Staying true to the innovative spirit of HNC, the exhibition spotlighted trending topics such as sports nutrition, aromatherapy, health foods and beverages, and the medicine and food homology, and curated several themed zones. Highlights included the brand-new "Hi Energy Camp", "Healing Workshop", "Light Wellness Awakening • Food & Beverage Festival", as well as the fully upgraded "TCM Nutrition Zone." These zones combined product showcases, competitions, and immersive experiences, while also collaborating for the first time with Douyin E-Commerce, the leading interest-based e-commerce platform, to offer brands live-streaming sales channels. This cross-ecosystem partnership empowered multiple brands to drive GMV growth and create best-selling products, putting innovative practice into action to boost domestic health consumption and reshape the health ecosystem through category evolution. All activities received enthusiastic feedback from onsite participants. As an industry hub for insights and exchange, the HNC 2025 also hosted more than 50 high-caliber industry events, reaching a new high in scale. The agenda covered professional industry conferences and forums, new product launches, international brand exchanges, innovative interactive experiences, business matchmaking, etc. Hot topics included weight management, applications of medicine and food homology, probiotic research, regulations and market trends for foods for special medical purposes (FSMPs), development of low-GI and whole-grain products, brand building and marketing strategies, hit product incubation, cross-border e-commerce strategies, nutrition across the life cycle, etc. Major events included the 14th Nutraceutical Industry Development Conference (NIDC), The 19th Innovation Hub for Nutrition and Health Food, The 2nd Jilin's Changbai Mountain Ginseng Health (Shanghai) Forum & Related Industry Economic and Trade Matchmaking, 2025 Industry Forum on Medicine and Food Homology, NutriGlobal 2025: Private Advisory Forum for Supply Chain Innovation in China's Health Market, among others. These sessions, held in both Chinese and bilingual formats, gathered government officials, industry association leaders, research experts, and business executives, who shared forward-looking insights and engaged in in-depth exchanges with attendees onsite. Meanwhile, to enhance the efficiency and precision of connections between exhibitors and channel partners, the HNC meticulously organized five targeted business matchmaking sessions onsite. Well-known MCN agencies were specially invited, along with top e-commerce influencers and leading private-domain group leaders, to source new products. Major offline supermarket chains and pharmacy chains also actively participated in the matchmaking sessions. Through this kind of business matchmaking model, broader and more diversified market channels are opened up for exhibitors. To enrich the overall experience for visitors, the HNC significantly upgraded its "Discovery Tour" interactive activity, carefully planning three themed tour routes: Beauty & Anti-Aging, Weight Management, and Tonic Food. Visitors showed great enthusiasm by checking in at booths to learn about the latest products and solutions under each theme. In addition, the HNC launched an all-new immersive cultural experience project called "Trendy Herbal Shop", showcasing the integration of food-medicine homology traditions, as well as a limited-time "Seal-Collecting Tour" activity, which added vibrant fun and cultural depth to the exhibition. The HNC 2025 in Shanghai has come to a successful close. The organizers would like to extend our heartfelt thanks to all exhibitors, professional visitors, partners, and media friends for their invaluable support and enthusiastic participation. Looking ahead, the next stop for HNC will be the "Healthplex Expo, Natural & Nutraceutical Products Shenzhen 2025" (HNC Shenzhen 2025), taking place from December 16 to 18, 2025, at the Shenzhen World Exhibition & Convention Center. Next year at the "Healthplex Expo 2026, Natural & Nutraceutical Products China 2026" (HNC 2026) in Shanghai, we expect to see you again from June 15th to 17th, 2026. We look forward to reuniting with colleagues from the global health and nutrition industry to share the grand occasions, and to jointly write an even more brilliant new chapter for the health industry. CONTACT USSINOEXPO INFORMA MARKETSEmail: HNCEXPO on Facebook / LinkedIn / X View original content: SOURCE Sinoexpo Informa Markets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
23-06-2025
- Business
- Globe and Mail
HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?
Hims & Hers Health ( HIMS ) has been one of the market's standout growth stocks in recent years. The company has successfully built a direct-to-consumer health platform targeting conditions like hair loss, mental health, and more recently, weight loss—delivering very strong revenue growth and stock returns. Shares had soared more than 150% (on two separate occasions) through the first half of 2025 before crashing more than 30% on Monday following a major partnership setback. The selloff was triggered by news that Novo Nordisk ( NVO ) will no longer partner with Hims to supply GLP-1 weight loss drugs like compounded semaglutide. Novo Nordisk cited HIMS' use of custom-compounded versions of its weight-loss drug, along with concerns over the company's sales and promotional tactics, as reasons for ending the partnership. While the termination of the partnership raises valid concerns for investors, Hims & Hers Health remains a fast-growing company operating in a compelling industry vertical. Below, we'll explore HIMS' business fundamentals, the broader GLP-1 industry landscape, and a tactical approach, the three-day rule, for those considering buying the stock. Hims and Hers Stock Rallied on Strong Growth Over the last two years, HIMS stock has been a huge gainer, though it has been accompanied by considerable volatility. Nonetheless, the company continues to enjoy some fairly compelling metrics and forecasts, especially following this large correction. The company currently holds a Zacks Rank #3 (Hold), indicating mixed, earnings revisions over the last two month. Today, HIMS trades at 41x next year's earnings, a premium valuation, but not unreasonable for a company with such strong growth forecasts. Earnings are expected to grow at an impressive 36.5% annually over the next three to five years, while sales are projected to rise 58.5% this year and another 22.6% next year. Novo Nordisk and Eli Lilly Stocks Have Traded Lower Interestingly, the GLP-1 giants have struggled over the last year. Shares of Novo Nordisk are still down more than 50% from their 2024 highs, while Eli Lilly ( LLY ) has shown more relative strength, though still well off its highs. Both stocks have faced their own challenges, including supply constraints, reimbursement questions, and competition in the obesity drug space. The outperformance of Eli Lilly and massive outperformance of Hims shows investors may favor these names. Despite the near-term volatility, long-term projections for the GLP-1 market remain massive. Some analysts estimate the global market for GLP-1 weight loss treatments could exceed $150 billion by 2035. While the loss of the Novo partnership is a setback, Hims may still have a path to participating in this growth, either through compounding or alternative partnerships. Three-Day Rule for Those Interested in Buying HIMS Stock For investors considering buying the dip, the three-day rule may be worth applying here. As explained in our recent article on UNH, sharp one-day drops on unexpected news often lead to additional downside or volatility in the short term. Giving the stock a few days to settle can help reduce risk and provide a clearer entry point. Should Investors Buy Shares in HIMS? HIMS is now a high-risk, high-reward growth stock. The long-term outlook remains compelling given the company's strong revenue growth, expanding customer base, and exposure to major healthcare trends. However, near-term uncertainty is high. The loss of the Novo partnership, regulatory ambiguity, and premium valuation all suggest caution. Investors may want to let the dust settle before taking a position, but for those willing to stomach the volatility, the selloff could present a long-term opportunity. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Reuters
18-06-2025
- Health
- Reuters
Exclusive: US to drop guidance to limit alcohol to one or two drinks per day, sources say
June 18 (Reuters) - U.S. Dietary Guidelines are expected to eliminate the long-standing recommendation that adults limit alcohol consumption to one or two drinks per day, according to three sources familiar with the matter, in what could be a major win for an industry threatened by heightened scrutiny of alcohol's health effects. The updated Dietary Guidelines for Americans, which could be released as early as this month, are expected to include a brief statement encouraging Americans to drink in moderation or limit alcohol intake due to associated health risks, the sources said. The guidelines are still under development and subject to change, two of the sources and a fourth individual familiar with the process said. Currently, the recommendations advise limiting drinking to one serving or less per day for women and two or less for men, widely seen as a moderate level. Similar guidelines exist in countries such as the United Kingdom, which advises limiting drinking to 14 units per week, while Canada, however, has adopted a more cautious stance, warning that health risks begin to increase after just two drinks per week. Even moderate drinking is linked to some health risks, such as higher risk of breast cancer, though some studies have also found an association with possible health benefits, such as a lower risk of stroke. The fourth source said that the scientific basis for recommending specific daily limits is limited, and the goal is to ensure the guidelines reflect only the most robust evidence. The new guidelines, developed by the U.S. Department of Health and Human Services and the U.S. Department of Agriculture, are closely watched internationally and influence policies ranging from school lunch programs to medical advice. Neither department responded to requests for comment. Health Secretary Robert F. Kennedy Jr., a known teetotaler, has remained largely silent on alcohol but has emphasised a focus on whole foods in the upcoming guidelines. Some alcohol executives had feared a move towards tighter recommendations on alcohol intake as authorities like the World Health Organization upped their warnings about alcohol's health risks. Former U.S. Surgeon General Vivek Murthy said alcohol consumption increases the risk of at least seven types of cancer and called for warning labels on alcoholic drinks. Major industry players, including Diageo (DGE.L), opens new tab and Anheuser-Busch InBev ( opens new tab, have lobbied lawmakers throughout the review process. Senate records show each company spent millions on lobbying efforts related to the guidelines and a range of other issues such as tax and trade in 2024 and 2025. Both companies declined to comment. The new guidelines are set to move away from suggesting consumers limit alcohol consumption to a specific number of daily servings, according to the three sources, who asked not to be named in order to speak freely. One person said the new alcohol-related recommendation will probably be limited to a sentence or two. Another said the existing numbers tied to moderate drinking could still appear in a longer appendix. While industry representatives have lobbied lawmakers on the guidelines or how they should be decided, some officials and researchers advocated for tighter restrictions. Reports intended to inform the guidelines have meanwhile drawn different conclusions about alcohol's health effects and the science around this. The guidelines, which are reviewed every five years, have advised drinking in moderation and defined that as no more than one drink per day for women and no more than two for men since 1990. Eva Greenthal, a senior policy scientist at the Center for Science in the Public Interest, a non-profit focused on nutrition, health and food safety, said the more general language expected in the guidelines was "so vague as to be unhelpful". Under such a change, the message that even moderate drinking can increase risks, especially for breast cancer, would get lost, she continued. Two studies were produced to inform the development of the guidelines. The first found that moderate drinking was associated with increased risk of some cancers, but a decreased risk of dying from any cause and some cardiovascular problems like stroke. The evidence for some other health impacts was insufficient to draw conclusions, it found. The other report conversely found the risk of dying from alcohol use, including increased risk for seven cancers, begins at any or low levels of alcohol use and increases with higher consumption.
Malay Mail
03-06-2025
- Business
- Malay Mail
Bensang Pharmaceuticals Officially Enters Japanese Duty-Free Market, Opening a New Chapter in Health Consumption
TOKYO, JAPAN - Media OutReach Newswire - 3 June 2025 - Bensang Pharmaceuticals (China), a leading health and wellness brand, announced today that its full product line has officially entered Tokyo duty-free stores, marking a deep collaboration in the health consumption sector. This partnership not only provides consumers with a global authentic purchasing channel but also integrates high-quality health products with the premium duty-free shopping Duty Free is a world-leading travel retail platform with a global supply chain network and millions of passenger flows, serving as a key gateway for premium brands entering international markets. Bensang Pharmaceuticals, with its scientific formulations, stringent quality control, and diverse product portfolio, has earned strong market recognition. The brand will set up exclusive display zones in duty-free stores and launch limited-time promotional offers to meet the diverse health product demands of both international travelers and local growing health awareness, wellness products have become a new growth driver in duty-free consumption. Bensang's commitment to R&D and product innovation aligns perfectly with Tokyo Duty Free's positioning as the "preferred destination for quality living."As China's health industry continues to expand, its market size is projected to exceed ¥20 trillion by 2025. Duty-free channels, with their "authenticity guarantee + competitive pricing," have become the top choice for high-net-worth individuals and cross-border shoppers. Bensang's entry into duty-free stores is a crucial step in its globalization strategy, driving the Chinese health supplement industry toward premium and international #BensangPharmaceuticals The issuer is solely responsible for the content of this announcement. About Bensang Pharmaceuticals Bensang Pharmaceuticals is dedicated to the R&D and production of high-quality health products, including dietary supplements, pharmaceuticals, and medical devices. The company aims to advance global health industry development and help people achieve a better quality of life.
